Skip to Main Content

Aurobindo Pharma, which is based in India and is one of the largest global producers of generic medicines, is closing its U.S. manufacturing facility in New Jersey next month, according to a notice filed with the state Department of Labor.

In its filing, the generic drug company disclosed it is terminating operations of its Aurolife Pharma unit in Dayton, N.J., and will eliminate a total of 99 jobs as of April 26. No further details were provided and calls to the facility were not returned. No one at Aurobindo headquarters in Hyderabad, India, could be reached for comment.


The move comes after Aurobindo, which is in the process of selling its injectables drug business, was cited in late 2020 by the U.S. Food and Drug Administration for a long list of manufacturing violations found at the facility during inspections conducted the year before. The issues were so extensive that the FDA suggested the company hired outside experts to fix the problems.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.